Adverse cardiac effects associated with anticancer drugs
With the development of new protein kinases, antibodies, immunomodulators and hormonal treatments, significant progress has taken place in the last few years in the pharmacological treatment of cancers. At the same time, old cytotoxic drugs still remain in use. In regard to the heart, anthracyclines are the most problematic cytotoxic drugs, as they may cause cardiac insufficiency that is manifested only years after the treatment. Also trastuzumab and kinase inhibitors may cause cardiac insufficiency. Fluoropyrimidines cause myocardial ischemia for some patients. Treatments targeting VEGF inhibition are frequently associated with significant elevation of blood pressure.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:131 |
|---|---|
| Enthalten in: |
Duodecim; laaketieteellinen aikakauskirja - 131(2015), 5 vom: 01., Seite 441-7 |
| Sprache: |
Finnisch |
|---|
| Weiterer Titel: |
Syöpälääkkeiden sydänhaitat |
|---|
| Beteiligte Personen: |
Piuhola, Jarkko [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 21.08.2015 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM251490149 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM251490149 | ||
| 003 | DE-627 | ||
| 005 | 20231224162126.0 | ||
| 007 | tu | ||
| 008 | 231224s2015 xx ||||| 00| ||fin c | ||
| 028 | 5 | 2 | |a pubmed24n0838.xml |
| 035 | |a (DE-627)NLM251490149 | ||
| 035 | |a (NLM)26237906 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fin | ||
| 100 | 1 | |a Piuhola, Jarkko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adverse cardiac effects associated with anticancer drugs |
| 246 | 3 | 3 | |a Syöpälääkkeiden sydänhaitat |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 21.08.2015 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a With the development of new protein kinases, antibodies, immunomodulators and hormonal treatments, significant progress has taken place in the last few years in the pharmacological treatment of cancers. At the same time, old cytotoxic drugs still remain in use. In regard to the heart, anthracyclines are the most problematic cytotoxic drugs, as they may cause cardiac insufficiency that is manifested only years after the treatment. Also trastuzumab and kinase inhibitors may cause cardiac insufficiency. Fluoropyrimidines cause myocardial ischemia for some patients. Treatments targeting VEGF inhibition are frequently associated with significant elevation of blood pressure | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Anthracyclines |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 700 | 1 | |a Tenhunen, Olli |e verfasserin |4 aut | |
| 700 | 1 | |a Kerkelä, Risto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Duodecim; laaketieteellinen aikakauskirja |d 1945 |g 131(2015), 5 vom: 01., Seite 441-7 |w (DE-627)NLM000016136 |x 0012-7183 |7 nnns |
| 773 | 1 | 8 | |g volume:131 |g year:2015 |g number:5 |g day:01 |g pages:441-7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 131 |j 2015 |e 5 |b 01 |h 441-7 | ||